|
Match
|
Document |
Document Title |
|
|
6106822 |
Hormone and growth factor phosphoglycokine mimetics from mycobacterium
A hormone or growth factor mimetic second messenger is derived from a microorganism of the genus Mycobacterium, suitably M. vaccae. The mimetic second messenger may mimic the action of insulin,...
|
|
|
6103224 |
N∇2 CSF-1 (short form) and carboxy truncated fragments thereof
A colony stimulating factor, CSF-1, is a lymphokine useful in regulating the immune system. is a lymphokine useful in overcoming the immunosuppression induced by chemotherapy or resulting from...
|
|
|
6099846 |
Enhancement of B cell lymphoma and tumor resistance using idiotype/cytokine conjugates
B cell lymphoma tumor-associated antigen or a fragment thereof containing an epitope are linked to an immune-enhancing cytokine, such as GM-CSF, IL-2, or IL-4 to form an immuno-complex. This...
|
|
|
6096300 |
Treatment of myeloproliferative disease with exodus chemokine
The present invention provides purified and isolated chemokine protein, fragments and polypeptide analogs thereof, antibodies thereto, and materials and methods for the recombinant production...
|
|
|
6096320 |
Vaccines with chimeric protein comprising gamma-interferon and leukotoxin derived from pasteurella haemolytica
New chimeric proteins, DNA encoding the same, and the use of these proteins in stimulating immunity against respiratory diseases such as pneumonia, including shipping fever pneumonia, are...
|
|
|
6093699 |
Method for gene therapy involving suppression of an immune response
A method for specifically suppressing the capacity of a mammal receiving gene therapy to mount an immune response to a given expressed gene of the deficient gene in question, which response is...
|
|
|
6093405 |
Inactive but immunogenic cytokines, pharmaceutical compositions containing same, and methods of treating homeostatic disorders associated with an overproduction of cytokines
Cytokines, which are biologically inactive in humans but remain immunogenic, are used in pharmaceutical compositions to promote a neutralizing immune response against native cytokines when...
|
|
|
6093390 |
Methods for promoting functional regeneration of mammalian muscle by administering leukaemia inhibitor factor
The present invention relates to a method for regulating neuron development, maintenance and regeneration in the central and peripheral nervous systems of a mammal and to pharmaceutical...
|
|
|
6093381 |
Modulation of the sensitivity of tumor cells to chemotherapeutics
Disclosed is a method for improving the treatment of a cancer patient which is undergoing (adjuvant) chemotherapy. Prior to or concomitant with the patient receiving adjuvant chemotherapy, the...
|
|
|
6093391 |
Peptide copolymer compositions
Compositions of peptides and block copolymers and methods of treatment using the same. The compositions enhance the activity of peptide-based and related biological agents, and reduce adverse side...
|
|
|
6090377 |
Monocyte activating cytokine
The present invention provides novel monocyte activating cytokine (MAC) and a polynucleotide encoding MAC. The invention also provides for genetically engineered expression vectors and host cells...
|
|
|
6090918 |
Receptor protein designated 2F1
2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting...
|
|
|
6086868 |
Method for treating or preventing ischemia-reperfusion injury
There is disclosed a method of treating ischemia-reperfusion injury comprising administering an effective amount of Interleukin-10 to a patient suffering or expected to suffer from such injury.
|
|
|
6086866 |
Use of platelet-derived growth factor to improve collateral circulation
The present invention provides a non-invasive method for improving collateral circulation to tissue at risk of ischemia or ischemic necrosis. Improved collateral circulation is obtained by applying...
|
|
|
6086865 |
Methods of treating angiogenesis-induced diseases and pharmaceutical compositions thereof
The present invention provides for the use of fumagillin or an O-substituted fumagillol derivative in conjunction with interferon which increases the angiogenic inhibitory action as compared with...
|
|
|
6086867 |
Modulation of TGF-β by TGF-β type III receptor polypeptides
DNA encoding TGF-β TYPE III receptor of mammalian origin, DNA encoding TGF-β type II receptor of mammalian origin, TGF-β type III receptor. TGF-β type II receptor and uses therefor.
|
|
|
6083534 |
Pharmaceutical compositions for controlled release of soluble receptors
A controlled release pharmaceutical composition includes a biocompatible polymeric material, preferably polyethylene-vinyl acetate or poly(lactic-glucolic acid), having incorporated therein a...
|
|
|
6084071 |
Human L105 polypeptides and polynucleotides encoding same
A chemokine, human L105, is disclosed.
|
|
|
6083907 |
Treatment of peptic ulcers using midkine (MK) proteins
An anti-ulcer composition is provided, which comprises as an active ingredient at least one of MK protein, its derivative having biological activity of MK protein, and their fragment having...
|
|
|
6083503 |
Interleukin-2 stimulated T lymphocyte cell death for the treatment of autoimmune diseases, allergic responses, and graft rejection
A method for the treatment or prevention of autoimmune diseases, allergic or atopic disorders, and graft rejection is provided, comprising inducing the death by apoptosis of a subpopulation of T...
|
|
|
6083906 |
Method of regulating nitric oxide production or arthritis with soluble IL-17 receptor
Methods for regulating levels of nitric oxide are disclosed. The methods utilize IL-17 receptors, which may be used in conjunction with inhibitor of IL-1 and/or TNF.
|
|
|
RE36755 |
DNA encoding tumor necrosis factor-α and -β receptors
Tumor necrosis factor receptor DNAs and expression vectors encoding TNF receptors, and processes for producing TNF receptors as products of recombinant cell culture, are disclosed.
|
|
|
6080398 |
Truncated gro and KC chemokines having enhanced bioactivity
The present invention provides method of increasing the biological activity of KC, gro-α, gro-β, and gro-γ proteins, truncated and modified proteins characterized by having biological activity...
|
|
|
6077519 |
Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients
Methods are provided for eluting peptides that are bound to major histocompatibility complex ("MHC") molecules expressed on the cell surfaces of viable cells that have at least one MHC-peptide...
|
|
|
6074635 |
T cell activation
Methods for activating T cells in the absence of antigen, and compositions for effecting the same, are described.
|
|
|
6074639 |
Ex vivo expansion of hematopoietic cells using interleukin-3 (IL-3) variant fusion proteins
The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF),...
|
|
|
6066318 |
Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors
Disclosed are novel multi-functional hematopoietic receptor agonist proteins, DNAs which encode the multi-functional hematopoietic receptor agonists proteins, methods of making the multi-functional...
|
|
|
6063757 |
Wound treatment method with nerve growth factor
A method is provided for healing chronic wounds in a subject, particularly wounds which exhibit poor vascularization and sensory loss. The treatment method involves administering a therapeutically...
|
|
|
6063373 |
Enhanced activation of NK cells using an NK cell activator and a hydrogen peroxide scavenger or inhibitor
An improved method for the prevention of the inactivation of natural killer (NK) cells and the enhanced activation of NK cells in the presence of monocytes using a combination of a natural killer...
|
|
|
6063372 |
Uses of mammalian CTLA-8 and related reagents
Compositions and methods for using CTLA-8 to treat an abnormal physiological condition in an individual. The methods comprise administering a therapeutically effective amount of CTLA-8 alone, or in...
|
|
|
6057133 |
Multivariant human IL-3 fusion proteins and their recombinant production
The present invention relates to fusion molecules composed of human interleukin-3 (hIL-3) variant or mutant proteins (muteins) functionally joined to a second colony stimulating factor (CSF),...
|
|
|
6048971 |
Recombinant human erythropoietin mutants
DNA encoding modified, secretable erythropoietin proteins whose ability to regulate the growth and differentiation of red blood cell progenitors are different from the wildtype recombinant...
|
|
|
6048837 |
OB polypeptides as modulators of body weight
The present invention relates generally to the control of body weight of animals including mammals and humans, and more particularly to materials identified herein as modulators of body weight, and...
|
|
|
6042821 |
Method of treating sepsis with chemokines
The invention relates to the method of preventing and treating sepsis using chemokines selected from mature or modified KC [SEQ ID NO: 1], groα [SEQ ID NO:2], groβ [SEQ ID NO: 3] or groγ [SEQ ID...
|
|
|
6043344 |
Human CTLA-8 and uses of CTLA-8-related proteins
Polynucleotides encoding human CTLA-8 and related proteins are disclosed. Human CTLA-8 proteins and methods for their production are also disclosed. Methods of treatment using human CTLA-8...
|
|
|
6042826 |
Method for inducing apoptosis of primary central nervous system B cell lymphomas
A method for treating a primary central nervous system lymphoma in an individual relates to administering intrathecally or intralesionally a therapeutically effective amount of a Fas-cross-linking...
|
|
|
6030812 |
Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins,...
|
|
|
6027720 |
G-CSF conjugate
Novel hG-CSF polypeptide derivatives having an amino acid sequence derived from the amino acid sequence of the human granulocyte colony stimulating factor polypeptide by substitution of at least...
|
|
|
6028050 |
Method for increasing platelets by administering soluble interleukin-6 receptor
A platelet-increasing preparation which comprises an effective amount of an interleukin-6 receptor and a pharmaceutically acceptable excipient. Preferably the preparation further comprises...
|
|
|
6025325 |
Pegylated obese (ob) protein compositions
Polyethylene and polypropylene protein conjugates which modulate body weight of animals and humans for the treatment, prevention and control of obesity and associated diseases or conditions, and...
|
|
|
6025324 |
Pegylated obese (ob) protein compositions
Polyethylene and polypropylene protein conjugates which modulate body weight of ani is and humans for the treatment, prevention and control obesity and associated diseases or conditions, and the...
|
|
|
6022535 |
Treatment of hematopoietic disorders with fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors
The present invention relates to human interleukin-3 (hIL-3) variant or mutant proteins (muteins) fused with other colony stimulating factors (CSF), cytokines, lymphokines, interleukins,...
|
|
|
6020323 |
Compositions and methods for regulation of active TNF-α
Substances comprising disaccharides and substances comprising carboxylated and/or sulfated oligosaccharides in substantially purified form, and methods of using same, are disclosed for the...
|
|
|
6019965 |
Methods for treatment of pulmonary disease using GM-CSF
Methods of treatment of pulmonary disease, e.g., alveolar proteinosis, by treating a subject with an effective amount of GM-CSF.
|
|
|
6017540 |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
The present invention relates to methods and compositions for eliciting an immune response and the prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases....
|
|
|
6017544 |
Composition comprising immunogenic stress protein-peptide complexes against cancer and a cytokine
Disclosed is a method for inhibiting the proliferation of a tumor in a mammal. The method involves the steps of (a) isolating a stress protein-peptide complex from tumor cells previously removed...
|
|
|
6015883 |
Rantes homolog from prostate
The present invention provides a polynucleotide (PTEC) isolated from a prostate cDNA library which identifies and encodes a novel human rantes homolog PTEC (prostate expressed chemokine). The...
|
|
|
6015552 |
Use of nerve growth factor-2 (NGF-2) /neurotrophin-3 (NT-3) to promote leukocyte proliferation
Human Nerve Growth Factor-2 (NGF-2, also known as Neurotrophin-3 or NT-3) has been found to promote the proliferation of peripheral blood leukocytes. The invention provides methods using hNGF-2...
|
|
|
6013252 |
Method promoting conception by administering IL-8 or MCAF
Leukocyte chemotactic factors such as interleukin-8 and MCAF, and inductive substances therefor were revealed to have proconceptive activities. These activities include promoting ovum growth and...
|
|
|
6008188 |
Cytokine potentiator and pharmaceutical formulation for cytokine administration
A cytokine activity enhancer comprising an ethanolamine derivative of the following general formula (I) or a salt thereof, or comprising it along with cytokine or a cytokine production promoter;...
|